Meta分析:炎症性肠病患者胰腺癌风险
该系统评价与Meta分析检索Embase、PubMed、Scopus和ProQuest至2023年10月31日,纳入13项研究(11项人群队列和2项孟德尔随机化研究),评估成人IBD患者胰腺癌风险。合并分析显示IBD患者胰腺癌风险增加79%(RR=1.79,95%CI 1.16-2.75),克罗恩病和溃疡性结肠炎风险相似,孟德尔随机化研究支持遗传易感IBD增加胰腺癌风险。
要点
- IBD患者胰腺癌风险增加79%(RR=1.79,95%CI 1.16-2.75)
- 克罗恩病与溃疡性结肠炎风险相似(交互作用P=0.72)
- IBD归因胰腺癌年发病率增加55例/百万(95%CI 17-103)
核心结论
- IBD患者胰腺癌风险中度增加,遗传易感IBD可能进一步增高该风险。
- 克罗恩病与溃疡性结肠炎的胰腺癌风险增加程度可能相似。
研究设计与样本
- 系统评价与随机效应Meta分析,检索Embase、PubMed、Scopus和ProQuest至2023年10月31日。
- 纳入13项研究,包括11项比较成人IBD与非IBD人群胰腺癌发病风险的人群队列研究,以及2项探讨IBD与胰腺癌风险关系的孟德尔随机化研究。
主要发现
- 11项队列研究合并分析显示,IBD患者发生胰腺癌风险增加79%(RR=1.79,95%CI 1.16-2.75;I²=95.7%)。
- 克罗恩病患者胰腺癌风险增加(RR=1.42,95%CI 1.24-1.63),溃疡性结肠炎患者风险亦增加(RR=1.50,95%CI 1.17-1.92),交互作用P=0.72。
- IBD归因的胰腺癌年发病率增加55例/百万(95%CI 17-103)。
- 两项孟德尔随机化研究显示,IBD遗传易感性与胰腺癌风险增加相关。
临床怎么用
- 对IBD患者应关注胰腺癌风险,尤其存在遗传易感背景者。
- 克罗恩病与溃疡性结肠炎患者均需考虑胰腺癌风险监测。
局限性
- 纳入研究间异质性高(I²=95.7%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Studies exploring the association between inflammatory bowel disease (IBD) and pancreatic cancer have reported inconsistent results. AIMS: To provide a comprehensive overview of the risk of pancreatic cancer development in patients with IBD. METHODS: We searched Embase, PubMed, Scopus and ProQuest from inception to 31 October 2023. We included population-based cohort studies examining the risk of incident pancreatic cancer in adult patients with IBD compared to the non-IBD population. We also retrieved Mendelian randomisation (MR) studies investigating the relationship of IBD with pancreatic cancer risk. We conducted random-effects meta-analyses and provided pooled relative risks (RRs) with 95% confidence intervals (CIs). RESULTS: We included 13 studies. Among 11 cohort studies, the risk of developing pancreatic cancer increased by 79% in patients with IBD (RR = 1.79 [95% CI: 1.16-2.75]; I2 = 95.7%). Patients either with Crohn's disease (RR = 1.42 [95% CI: 1.24-1.63]) or ulcerative colitis (RR = 1.50 [95% CI: 1.17-1.92]) had increased risk (p for interaction = 0.72). The annual incidence of pancreatic cancer potentially attributable to IBD increased by 55 cases (95% CI: 17-103) per million. Two MR studies demonstrated that genetic liability to IBD was associated with an increased risk of pancreatic cancer. CONCLUSIONS: Our results suggest a moderate increase in the risk of pancreatic cancer in patients with IBD, which may be further heightened by genetic predisposition to IBD. The increased risk of pancreatic cancer is probably similar in Crohn's disease and ulcerative colitis.
引用
- Zamani M, Alizadeh-Tabari S, Murad MH, et al. Meta-analysis: Risk of pancreatic cancer in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2024. PMID: 38372406. doi:10.1111/apt.17919
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。